COMMUNIQUÉS West-GlobeNewswire
-
CMR Surgical secures 510(k) clearance of its Versius Plus robotic surgical system
17/12/2025 -
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers
17/12/2025 -
Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets
17/12/2025 -
Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting
17/12/2025 -
Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
17/12/2025 -
Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package
17/12/2025 -
Beyond Air® Signs New International LungFit PH® Distribution Agreements, Most Notably in Germany and Brazil
17/12/2025 -
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference
17/12/2025 -
SAFE ANNONCE LA SIGNATURE D'UN CONTRAT DE DISTRIBUTION STRATEGIQUE EN ESPAGNE AVEC VORTROM BIOLOGICS
17/12/2025 -
SAFE SIGNS A STRATEGIC DISTRIBUTION AGREEMENT IN SPAIN WITH VORTROM BIOLOGICS
17/12/2025 -
CMR Surgical secures 510(k) clearance of its Versius Plus robotic surgical system
17/12/2025 -
Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic
17/12/2025 -
Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering
17/12/2025 -
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California
17/12/2025 -
Festive drinking and hormones: Clue shares science-backed guidance for Christmas
17/12/2025 -
Communiqué de presse : L’efdoralprine alfa de Sanofi obtient la désignation de médicament orphelin dans l’UE pour l’emphysème lié au déficit en alpha-1-antitrypsine
17/12/2025 -
Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
17/12/2025 -
Nyxoah Annonce le Lancement Commercial de la Thérapie Innovante Genio® Aux Pays-Bas
17/12/2025 -
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands
17/12/2025
Pages